Study of treatment effects after chemotherapy and surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have resectable stage IIIA non-small cell lung cancer (NSCLC).
- Your cancer tests showed lymph node involvement (N2) confirmed by biopsy or pathology.
- Your diagnosis happened between 2010 and June 2017.
- You received chemotherapy before surgery that included a platinum drug.
- You had surgery after the chemotherapy, meaning the tumor was removed.
- Your diagnosis included a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This Phase II trial tests whether a penpulimab-based combination treatment, given before and after surgery, can improve outcomes for people with operable, locally advanced non-small cell lung cancer. It mainly aims to treat the cancer earlier (before surgery) and help prevent it from coming back (after surgery).
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
Hear when a new Stage IIIA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.